🔍

Sun Pharma Advanced Research Company Limited (SPARC)

₹188.64 +0.18% last close, 16 Oct

📊 NSE: SPARC 🏢 Pharmaceuticals 📢 Latest filing: 07 Oct 2026 📝 Analysis written: 14 Dec 2025

Latest quarterly results (Q1 FY27)

In its latest reported quarter, Q1 FY27, Sun Pharma's revenue was ₹39.9 Cr (+314.1% year on year, -97.8% on the previous quarter), and net profit ₹-20.8 Cr (a smaller loss than a year earlier); the operating margin was -85.2%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹39.9	+314.1%	-97.8%
Operating profit	₹-34.0	loss narrowed	to loss
Net profit	₹-20.8	loss narrowed	to loss
EPS (₹)	-0.64	loss narrowed	to loss
Operating margin	-85.2%	—	—

Full quarterly financials → Results calendar →

SPARC delivery percentage

NSE end-of-day data for Fri, 16 Oct 2026

On Fri, 16 Oct 2026, 35.1% of the SPARC shares traded on NSE were taken to delivery, against the stock's own 20-session average of 40.9%. That is close to its usual level. Volume was 0.5 times its average, well below normal.

35.1%Delivery, 16 Oct

40.9%Own 20-session average

0.5×Volume vs its average

₹188.64NSE close · +0.18%

Delivery in the last 5 sessions: 37.9% · 35.0% · 30.3% · 43.0% · 35.1%

Delivery across the market →

A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed

📢 Recent Corporate Announcements

SPARC Submits Dematerialisation Certificate for Quarter Ended September 30, 2026

🟡 NEUTRAL ⭐ 1/10

ROUTINE 📅 07 Oct 2026, 10:31 AM

Sun Pharma Advanced Research Company Limited (SPARC) has submitted its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate was issued by Registrar and Share Transfer Agent MUFG Intime (India) Private Limited on October 03, 2026, for the quarter ended September 30, 2026. It confirms that securities received for dematerialisation during the period were duly processed, verified, and cancelled, with the depository substituted as the registered owner. This is a mandatory, procedural quarterly filing with no operational or financial impact.

Compliance submission under Regulation 74(5) of SEBI (DP) Regulations, 2018
Pertains to the quarter ended September 30, 2026
RTA confirmation certificate dated October 03, 2026, issued by MUFG Intime (India) Private Limited

💡 No action is required as this is a recurring regulatory compliance filing. Investors should monitor SPARC's upcoming quarterly financial results and clinical pipeline updates for fundamental insights.

SPARC Wins CESTAT Tax Dispute, Entitled to ₹27.51 Cr CENVAT Refund with Interest

🟢 POSITIVE ⭐ 5/10

LEGAL 📅 04 Oct 2026, 12:48 PM

Sun Pharma Advanced Research Company (SPARC) received a favorable ruling from the Customs, Excise & Service Tax Appellate Tribunal (CESTAT), Mumbai. CESTAT dismissed the Revenue's appeal and upheld the Order-in-Appeal dated April 27, 2018. As a result, the company's entitlement to a refund of accumulated CENVAT credit amounting to ₹27.51 crore (₹2,751 lakhs), along with applicable interest, has been confirmed. This refund represents approximately 1.4% of SPARC's TTM revenue of ₹1,909 crore and will provide a positive one-time cash inflow.

CESTAT Mumbai dismissed the Revenue department's appeal, ruling in favor of SPARC.
Order-in-Appeal dated April 27, 2018 was upheld by the Tribunal.
Company is entitled to a refund of accumulated CENVAT credit of ₹2,751 lakhs (₹27.51 crore) plus consequential interest.
Refund amount equals roughly 1.4% of SPARC's TTM revenue of ₹1,909 crore.

💡 Monitor upcoming quarterly filings to track the receipt and accounting treatment of the ₹27.51 crore cash refund and accrued interest, as well as checking if the Revenue department challenges the order in a higher court.

SPARC Files Application for Reclassification of Promoter Group to Public Category

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 13 Aug 2026, 04:44 PM

Sun Pharma Advanced Research Company (SPARC) has formally submitted an application to the NSE and BSE on August 13, 2026, for the reclassification of certain entities from the 'Promoter Group' to the 'Public' category. This follows the company's previous board-level intimations on July 27 and August 10, 2026. The move is a procedural step under Regulation 31A of SEBI LODR and typically aims to streamline the shareholding structure. As of June 2026, the promoter holding in the company stands at 65.67%.

Application filed with stock exchanges on August 13, 2026, for reclassification under Regulation 31A.
Follows two prior intimations dated July 27, 2026, and August 10, 2026.
Current promoter holding remains at 65.67% as per the latest June 2026 filing.
Company maintains a market capitalization of Rs 6632 Cr with a TTM revenue of Rs 1879 Cr.

💡 Investors should watch for the stock exchanges' 'No Objection Certificate' or approval, which will finalize the change in the shareholding classification. This is a procedural event and does not impact the company's R&D operations or clinical pipeline.

$195 Million PRV Monetization and New MD & CEO Appointment Confirmed at SPARC AGM

🟢 POSITIVE ⭐ 8/10

MANAGEMENT 📅 10 Aug 2026, 07:39 PM

SPARC's 21st AGM confirmed the appointment of Mr. Anil Kumar Raghavan as MD & CEO, following the retirement of Dr. Rajamannar Thennati. The company highlighted a major financial milestone: the monetization of a Pediatric Rare Disease Voucher (PRV) for $195 million (approx. ₹1,630 cr), which has rendered the company debt-free. While FY26 financials were bolstered by this one-time gain, the company reported a regulatory delay for PDP-716 due to manufacturing site compliance issues. R&D focus remains on oncology and immunology, with interim data for SPARC-121 expected in FY2026-27.

Monetized Pediatric Rare Disease Voucher (PRV) for $195 million, significantly strengthening the balance sheet.
Company is now debt-free following the PRV monetization and cost rationalization measures.
Consolidated laboratory infrastructure from 4 sites to 2 to improve operational efficiency.
Interim data for SPARC-121 (Alopecia Areata) Phase 1b study expected during FY2026-27.
PDP-716 regulatory approval delayed due to compliance issues at the finished product manufacturing site.

💡 Investors should monitor the resolution timeline for PDP-716 manufacturing compliance and the upcoming Phase 1b data for SPARC-121 in FY27. The utilization of the $195 million cash pile for pipeline advancement without further dilution is a key metric to track.

SPARC Q1 FY27: ₹1,630 Cr PRV Sale Realized; Loss Narrows to ₹20.98 Cr

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 10 Aug 2026, 01:56 PM

SPARC reported a standalone net loss of ₹20.98 Cr for Q1 FY27, a significant improvement from the ₹52.03 Cr loss in Q1 FY26. Revenue from operations rose to ₹39.92 Cr, supported by the recognition of ₹29.21 Cr following the termination of a licensing agreement with CMS Bridging DMCC. A major liquidity milestone was achieved with the sale of a Priority Review Voucher (PRV) for $195 million (approx. ₹1,630 Cr) on April 30, 2026. Furthermore, the company strengthened its capital base by allotting 3.85 crore warrants to the promoter group at ₹155.80 per share, receiving 25% of the subscription money.

Realized $195 million (approx. ₹1,630 Cr) from the sale of a Priority Review Voucher (PRV) on April 30, 2026
Standalone net loss narrowed to ₹20.98 Cr in Q1 FY27 from ₹52.03 Cr in the same quarter last year
Allotted 3.85 crore warrants to promoter entity Shanghvi Finance at ₹155.80 per share on May 19, 2026
Recognized ₹29.21 Cr in revenue from a terminated licensing agreement with CMS Bridging DMCC after a $2 million refund
Total income for the quarter stood at ₹63.58 Cr, up from ₹18.66 Cr in Q1 FY26

💡 Investors should monitor the deployment of the ₹1,630 Cr PRV proceeds into the R&D pipeline and the clinical trial progress of the 5 products currently in clinical stages. The conversion of the remaining 75% of promoter warrants (₹116.85 per warrant) over the next 18 months will be a key liquidity event.

SPARC Q1 FY27: Revenue at ₹39.92 Cr; Net Loss Narrows to ₹20.78 Cr

🟡 NEUTRAL ⭐ 6/10

EARNINGS 📅 10 Aug 2026, 01:34 PM

SPARC reported a consolidated net loss of ₹20.78 Cr for the quarter ended June 30, 2026, showing improvement from a ₹51.87 Cr loss in the same period last year. Revenue from operations stood at ₹39.92 Cr, significantly higher than the ₹9.64 Cr reported in Q1 FY26, primarily due to recognizing ₹29.21 Cr from a terminated licensing agreement. The company confirmed the sale of its Priority Review Voucher (PRV) for $195 million on April 30, 2026, providing a substantial cash buffer. Additionally, the board approved the reclassification of certain promoter group individuals to the public category.

Consolidated revenue from operations increased to ₹39.92 Cr in Q1 FY27 from ₹9.64 Cr in Q1 FY26.
Net loss narrowed to ₹20.78 Cr compared to a loss of ₹51.87 Cr in the year-ago quarter.
Recognized ₹29.21 Cr in revenue following the mutual termination of a licensing agreement with CMS Bridging DMCC.
Completed the sale of a Priority Review Voucher (PRV) for USD 195 million on April 30, 2026.
Allotted 3,85,10,000 warrants to Shanghvi Finance Private Limited at ₹155.80 per warrant on May 19, 2026.

💡 Investors should monitor the deployment of the $195 million PRV proceeds into the R&D pipeline and watch for clinical trial updates on the 5 products currently in clinical stages.

1.85% Stake Reclassification: Promoter Group Members Seek 'Public' Status

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 27 Jul 2026, 06:15 PM

SPARC has received formal requests from three members of its Promoter Group to be reclassified as 'Public' shareholders. The individuals involved—Mr. Sudhir Valia, Mrs. Raksha Valia, and Mrs. Krishna Valia—collectively hold 59,79,182 shares, representing 1.85% of the company's total equity. This request is a regulatory procedure under SEBI Listing Regulations and does not involve an immediate sale of shares. The company's Board of Directors will now examine the request before seeking final approval from stock exchanges.

Total shares proposed for reclassification amount to 59,79,182 units.
The combined holding of the requesting parties represents 1.85% of the total equity.
Mrs. Raksha Sudhir Valia holds the largest portion among the applicants at 41,45,231 shares (1.28%).
Mr. Sudhir Vrundavandas Valia holds 18,33,951 shares (0.57%).
The request was formally received by the company on July 27, 2026.

💡 Investors should treat this as a procedural regulatory filing. Watch for the Board's approval and subsequent stock exchange confirmation to see the updated shareholding pattern in future quarters.

SPARC Schedules 21st AGM for Aug 10; Corporate Guarantee Increased to ₹545 Cr

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 16 Jul 2026, 08:45 PM

Sun Pharma Advanced Research Company (SPARC) has issued its FY 2025-26 Annual Report and scheduled its 21st AGM for August 10, 2026. A key financial disclosure includes the corporate guarantee from promoter-linked Shanghvi Finance Private Limited increasing significantly to ₹545 crore from ₹200 crore. The report also notes a reclassified milestone payment of USD 5 million (₹47.17 crore) and the incorporation of a new subsidiary, Genokine Biotech Limited. While TTM revenue shows a massive spike to ₹1,879 crore due to a one-off Q4 FY26 performance, the company remains heavily dependent on the Sun Pharma Group for licensing and financial backing.

21st Annual General Meeting scheduled for August 10, 2026, via video conferencing
Corporate guarantee from Shanghvi Finance Private Limited increased by 172% to ₹545 crore
Milestone payment of USD 5 million (₹47.17 crore) reclassified from deferred revenue to other financial liabilities
CEO Anil Kumar Raghavan's remuneration for FY26 reported at ₹5.88 crore
Incorporated new subsidiary Genokine Biotech Limited on July 04, 2025, with an initial investment of ₹1.00 lakh

💡 Investors should monitor the AGM for management commentary on the clinical trial progress of the 5 products currently in clinical stages and the commercialization roadmap for Sezaby.

SPARC Appoints CEO Anil Raghavan as Managing Director Effective August 11, 2026

🟡 NEUTRAL ⭐ 7/10

MANAGEMENT 📅 13 Jul 2026, 05:37 PM

SPARC has announced a leadership transition where the current CEO, Mr. Anil Raghavan, will be elevated to the role of Managing Director and CEO effective August 11, 2026. This follows the retirement of Dr. Rajamannar Thennati from the Board on August 10, 2026, upon the completion of his term. The appointment is subject to shareholder approval at the upcoming 21st Annual General Meeting. This move ensures continuity in leadership for the company, which recently reported a significant TTM revenue of Rs 1879 Cr, largely driven by a massive Mar 2026 quarter.

Mr. Anil Raghavan appointed as MD & CEO effective August 11, 2026
Dr. Rajamannar Thennati to retire from the Board on August 10, 2026
The 21st Annual General Meeting (AGM) is scheduled for August 10, 2026
Company manages a pipeline of 5 clinical-stage products and 10+ pre-clinical assets
TTM Revenue stands at Rs 1879 Cr following a Rs 1853 Cr licensing-driven Mar 2026 quarter

💡 Monitor the 21st AGM proceedings on August 10, 2026, for formal shareholder approval and any strategic commentary from the new MD regarding the 'NewCo' creation model.

SPARC to Hold 21st Annual General Meeting on August 10, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 06 Jul 2026, 12:36 PM

Sun Pharma Advanced Research Company (SPARC) has scheduled its 21st Annual General Meeting (AGM) for August 10, 2026, via video conferencing. The company has fixed August 03, 2026, as the cut-off date to determine shareholder eligibility for voting on resolutions. This meeting follows a volatile financial year where TTM revenue reached Rs 1,879 Cr, heavily skewed by a single quarter (Mar 2026) reporting Rs 1,853 Cr, likely due to a milestone payment. Investors should look for the upcoming Annual Report for detailed updates on their R&D pipeline and commercialization strategy.

21st Annual General Meeting scheduled for August 10, 2026, at 04:30 P.M. IST
Cut-off date for voting eligibility and AGM attendance fixed for August 03, 2026
TTM revenue stands at Rs 1,879 Cr, with a massive Rs 1,853 Cr recorded in the March 2026 quarter alone
Promoter holding remains stable at 65.68% as of May 2026
Company continues to focus on its pipeline of 5 clinical-stage products and 10+ pre-clinical assets

💡 Investors should review the Annual Report once released on the company website to understand the sustainability of the recent revenue spike and the progress of clinical trials in Oncology and Neuro Degeneration.

SPARC Submits Quarterly Compliance Certificate under SEBI Regulation 74(5)

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 06 Jul 2026, 11:55 AM

Sun Pharma Advanced Research Company (SPARC) has submitted its quarterly compliance certificate for the period ended June 30, 2026. The filing, mandated under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, confirms that the company's Registrar and Share Transfer Agent, MUFG Intime (India) Private Limited, has processed all dematerialization requests. The registrar confirmed that physical certificates were mutilated and cancelled, and the records were updated with the depositories. This is a standard administrative procedure and does not impact the company's financial or operational status.

Compliance report covers the quarter ended June 30, 2026
Confirmation certificate received from Registrar MUFG Intime (India) Private Limited dated July 01, 2026
Verification and cancellation of physical security certificates completed as per SEBI norms
Confirmation that dematerialized securities are listed on the stock exchanges where earlier securities were listed

💡 This is a routine regulatory filing. No action is required from investors. Focus should remain on the company's R&D pipeline and clinical trial outcomes.

SPARC Announces Retirement of COO Dr. Nitin Dharmadhikari and Appointment of New HR Head

🟡 NEUTRAL ⭐ 5/10

MANAGEMENT 📅 26 Jun 2026, 06:27 PM

Sun Pharma Advanced Research Company (SPARC) has announced the retirement of two senior management personnel, including Chief Operating Officer Dr. Nitin Dharmadhikari and HR Head Ms. Shanta Gupta, effective June 30, 2026. To ensure leadership continuity, the company has appointed Mr. Prasanna Deshmukh as the new Functional Head of HR & Administration starting July 1, 2026. Mr. Deshmukh transitions from the parent group, Sun Pharmaceutical Industries Ltd, where he served as HR Business Partner for Global Quality and Compliance. The retirement of the COO is a significant change for the R&D-focused firm, though the transition appears to be a planned administrative cycle.

Dr. Nitin Dharmadhikari, Chief Operating Officer, to retire effective June 30, 2026.
Ms. Shanta Gupta, Functional Head – HR & Administration, to retire effective June 30, 2026.
Mr. Prasanna Deshmukh appointed as new HR & Admin Head effective July 1, 2026.
Incoming HR Head joins from Sun Pharmaceutical Industries Ltd (SPIL) with a background from Marico and Crompton.

💡 Investors should monitor for a follow-up announcement regarding the appointment of a new Chief Operating Officer to ensure operational stability. The transition in the HR department is well-managed through an internal group transfer, suggesting no immediate risk to organizational culture.

SPARC Terminates License Agreement with CMS Bridging DMCC for Greater China Region

🟡 NEUTRAL ⭐ 6/10

REGULATORY 📅 25 Jun 2026, 06:32 PM

Sun Pharma Advanced Research Company (SPARC) has mutually terminated its 2019 license agreement with CMS Bridging DMCC. The agreement was originally intended for the development and commercialization of five key products—Xelpros, Elepsia, Taclantis, PDP-716, and SDN-037—in Mainland China, Hong Kong, Macao, and Taiwan. The company has explicitly stated that this termination will have no material impact on its financial position or operational activities. This move suggests a shift in SPARC's regional strategy or a re-evaluation of the commercial potential of these assets in the Greater China market.

Mutual termination of the license agreement dated November 05, 2019, effective June 25, 2026.
Agreement covered 5 specific products: Xelpros, Elepsia, Taclantis, PDP-716, and SDN-037.
The affected territories included Mainland China, Hong Kong, Macao, and Taiwan.
Management confirms no material impact on the company's financial position or operations.

💡 Investors should monitor for any future announcements regarding new partnerships for these products in the China region or if the company plans to pursue these markets independently. The neutral impact suggests the deal was not currently a major revenue driver.

SPARC to Close Trading Window from July 1, 2026, for Q1 Financial Results

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 24 Jun 2026, 04:02 PM

Sun Pharma Advanced Research Company Limited (SPARC) has announced the closure of its trading window for all designated persons and their immediate relatives starting July 1, 2026. This move is a standard regulatory requirement under SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the declaration of financial results. The closure pertains to the unaudited financial results for the quarter ending June 30, 2026. The trading window will remain closed until 48 hours after the results are officially declared to the stock exchanges.

Trading window closure effective from Wednesday, July 1, 2026
Closure is for the purpose of declaring Unaudited Financial Results for the quarter ended June 30, 2026
Window to reopen 48 hours after the board meeting and results declaration
The specific date for the Board Meeting will be announced in due course

💡 This is a routine regulatory announcement with no impact on company fundamentals. Investors should wait for the announcement of the board meeting date to assess the upcoming quarterly performance.

SPARC Partner Receives US FDA CRL for PDP-716 NDA Over Manufacturing Issues

🔴 NEGATIVE ⭐ 7/10

REGULATORY 📅 19 May 2026, 06:45 PM

Sun Pharma Advanced Research Company (SPARC) announced that its licensing partner, Ocuvex Therapeutics Inc., has received a Complete Response Letter (CRL) from the US FDA for the PDP-716 New Drug Application. The CRL was issued specifically due to inspection findings at the finished product manufacturing facility, rather than clinical or safety concerns. While the FDA did not raise any other issues with the NDA, this development delays the potential commercialization and revenue generation from this product. Investors should note that the path to approval now depends on the successful remediation of the manufacturing facility's deficiencies.

US FDA issued a Complete Response Letter (CRL) for the PDP-716 New Drug Application (NDA).
The CRL is attributed to inspection findings at the finished product manufacturing facility.
FDA confirmed no other issues or deficiencies were raised regarding the PDP-716 NDA itself.
The licensing partner involved in the US market for this drug is Ocuvex Therapeutics Inc.
Approval and subsequent launch of PDP-716 will be delayed until manufacturing issues are resolved.

💡 Investors should monitor for updates regarding the remediation of the manufacturing facility and the timeline for a potential resubmission to the FDA. The stock may face short-term pressure due to the delay in expected milestone or royalty income.

View All SPARC Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Total revenue declined by 68.3% YoY to INR 75.55 Cr in FY24 from INR 238.78 Cr in FY23. Revenue is primarily derived from license fees, royalties, and R&D services. 9MFY25 revenue stood at INR 44.58 Cr, a 24.4% decrease compared to INR 58.99 Cr in 9MFY24, driven by a decline in license fees and the failure of the Proseek study.

Geographic Revenue Split

While specific SPARC geographic splits are not detailed, the company operates R&D centers in Mumbai and Vadodara (India) and New Jersey (USA). Its primary licensing partner, Sun Pharma, generates 65% of its consolidated revenue from overseas markets, including the USA, Europe, and emerging markets.

Profitability Margins

The company reported an operating loss of INR 387.22 Cr in FY24 compared to a loss of INR 222.58 Cr in FY23, resulting in a negative operating margin exceeding 500%. Net worth deteriorated by 75.5% to INR 125.57 Cr as of March 31, 2024, from INR 512.43 Cr in the previous year due to sustained R&D losses.

EBITDA Margin

EBITDA remains deeply negative due to the capital-intensive nature of R&D. Operating losses increased by 74% YoY in FY24. For 9MFY25, losses stood at INR 282.74 Cr, nearly flat compared to INR 281.42 Cr in 9MFY24, reflecting high fixed costs for clinical trials and workforce compensation.

Capital Expenditure

SPARC received INR 703 Cr in January 2023 through the conversion of warrants to fund R&D. The company has obtained shareholder approval to raise up to INR 1,800 Cr via fresh equity issuance to shore up its capital base and fund ongoing clinical trials.

Credit Rating & Borrowing

The company holds an ACUITE AA | Stable rating for its INR 200 Cr bank facilities. Borrowing costs are supported by a corporate guarantee from Shanghvi Finance Private Limited (SFPL). Total debt increased to INR 61.15 Cr in FY24 from INR 15.68 Cr in FY23, raising the gearing ratio from 0.03x to 0.49x.

⚙️ Operational Drivers

Raw Materials

The primary 'inputs' are a highly qualified scientific workforce (compensation) and clinical trial materials/services, which constitute the bulk of the R&D expenditure. Specific chemical raw material percentages are not disclosed as the company is clinical-stage, not a mass manufacturer.

Import Sources

R&D activities and clinical trials are conducted across India and the USA, with specialized materials sourced globally to meet USFDA and other regulatory standards.

Key Suppliers

Not specifically disclosed; however, the company utilizes specialized Contract Research Organizations (CROs) and clinical trial sites globally.

Capacity Expansion

SPARC operates R&D centers in Mumbai and Vadodara, India, and an office in New Jersey, USA. Expansion is focused on the pipeline rather than physical manufacturing, with 5 products in various clinical stages and 10+ pre-clinical assets.

Raw Material Costs

R&D costs are the primary driver of the cash flow mismatch. In FY22, operating losses were INR 186.75 Cr against revenue of INR 137.25 Cr, indicating that R&D and clinical costs regularly exceed 200% of annual revenue.

Manufacturing Efficiency

Not applicable as a clinical-stage company; efficiency is measured by the progression of assets through clinical phases (Phase I to III) and successful USFDA filings.

Logistics & Distribution

Distribution is handled by licensing partners. For example, Sezaby commercialization rights in the US were licensed to Sun Pharmaceutical Industries Inc. for an upfront payment of $10 million.

📈 Strategic Growth

Growth Strategy

Growth is targeted through the commercialization of the R&D pipeline, specifically NCEs (New Chemical Entities) and NDDS (New Drug Delivery Systems). The strategy includes signing licensing agreements for milestone payments and royalties, and potentially exploring a services model to leverage discovery capabilities.

Products & Services

Sezaby (phenobarbital sodium for neonatal seizures), technology licenses, and R&D services in Oncology, Neuro Degeneration, Ophthalmology, and Dermatology.

Brand Portfolio

SPARC, Sezaby.

New Products/Services

Pipeline includes 5 products targeting epilepsy, glaucoma, cancer, and Parkinson's disease, plus 10+ pre-clinical assets. Sezaby recently transitioned to commercialization via Sun Pharma.

Market Expansion

Focus is on the US market for specialty medications and global licensing. The company is evaluating a shift toward a 'NewCo' creation model for specific programs to de-risk development.

Market Share & Ranking

First listed pharma R&D company in India. Sun Pharma (parent/partner) is the 4th largest specialty generic company in the USA.

Strategic Alliances

Key alliance with Sun Pharmaceutical Industries Limited (SPIL) for commercialization and a collaboration with UCSF (University of California, San Francisco) for early-stage research.

🌍 External Factors

Industry Trends

The pharmaceutical R&D industry is shifting toward specialty medications and NCEs. SPARC is positioned in high-growth areas like Oncology and Neuro Degeneration, though it faces high risks associated with long gestation periods (5-10 years per drug).

Competitive Landscape

Competes with global biotech and specialty pharma companies like Merck, Sanofi, and Dr. Reddy's. Competition is based on clinical efficacy and time-to-market.

Competitive Moat

Moat is built on a robust patent portfolio, a pipeline of 15+ assets, and the financial backing of the Sun Pharma Group. Sustainability depends on successful clinical outcomes and the ability to raise capital during long gestation periods.

Macro Economic Sensitivity

Highly sensitive to global healthcare funding and regulatory environments. Inflation in clinical trial costs and specialized labor directly impacts the burn rate.

Consumer Behavior

Demand is driven by unmet medical needs in chronic and life-threatening diseases (e.g., Parkinson's, Cancer).

Geopolitical Risks

Trade barriers or regulatory changes in the US (USFDA) are critical, as the US is the primary target market for SPARC's innovative products.

⚖️ Regulatory & Governance

Industry Regulations

Strict adherence to USFDA and Indian regulatory standards for clinical trials, product safety testing, and manufacturing quality is mandatory. Any regulatory action can impair the value of products under development.

Environmental Compliance

ESG risks include hazardous substance release and toxic greenhouse gas emissions. Compliance is critical for maintaining R&D licenses in India and the USA.

Taxation Policy Impact

Not specifically detailed, but the company incurs losses, resulting in deferred tax assets rather than immediate tax liabilities.

Legal Contingencies

The company faces inherent legal risks associated with patent filings and clinical trial compliance. While specific pending court case values are not listed, regulatory setbacks are identified as a primary rating sensitivity.

⚠️ Risk Analysis

Key Uncertainties

The primary risk is the failure of clinical trials (e.g., Proseek), which can result in a 100% loss of investment for that specific asset. Long gestation periods create a permanent mismatch between R&D spend and revenue generation.